Protherics AstraZeneca Patent and Know-How License Agreement of December 7, 2005

Protherics AstraZeneca Patent and Know-How License Agreement of December 7, 2005 won the Scrip Awards Licensing Deal of the Year for 2006.

From the Form 6-K of December 8, 2005:

• currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the FDA
• the initial target indication is severe sepsis
• AstraZeneca will be responsible for development
• Protherics will be primarily responsible for manufacturing, including the supply for clinical trials
• initial payment of GBP16.3 million
• potential total deal value, excluding royalties, of approximately GBP195 million
• GBP7.5 million equity investment in Protherics at a30 percent premium
• AstraZeneca will own approximately 4.3 percent of Protherics
• GBP171 million payable upon the achievement of milestones
• no milestone s related to sales performance
• royalties on global product sales of 20 percent of net sales
• additional payments for the commercial supply of the product and will invest to expand its manufacturing capacity accordingly.